|
|
Article: Statement by Derma Sciences.
- Article from:
- PR Newswire
- Article date:
- September 18, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PRINCETON, N.J., Sept. 18 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (BULLETIN BOARD: DSCI) said today that it knows of no fundamental reason behind the decline in its stock price. The Company is baffled by the current stock price, as they are generating over $50 million in sales, over $15 million in Gross Profits and at the end of second quarter they had over $4 million in cash. By October the Company will have introduced four new patented products led by MEDIHONEY(TM), which is receiving excellent reviews in the marketplace and its sales are increasing better then planned.
Chairman & CEO Ed Quilty said, "Derma Sciences is growing quickly, and currently ...